PYPD
HealthcarePolyPid Ltd.
$4.47
+$0.12 (+2.76%)
Jan 5, 2026
Price History (1Y)
Analysis
PolyPid Ltd. is a biotechnology company operating in the healthcare sector with a market capitalization of $74.36M and approximately 57 employees. The company's financial health indicates significant losses, with net income (TTM) of -$34,216,000 and EBITDA of -$31,186,000. Gross margin, operating margin, and profit margin are all at 0.0%. Returns on equity and assets are negative at -390.5% and -87.9%, respectively. The debt-to-equity ratio is 28.23, while cash reserves stand at $18.79M with a total debt of $4.34M. The company's valuation metrics include a forward P/E ratio of -3.53, an EV/EBITDA ratio of -1.86, and a price to book ratio of 4.84. The beta is 1.51, indicating moderate volatility relative to the market.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About PolyPid Ltd.
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Visit website →Key Statistics
- Market Cap
- $74.36M
- P/E Ratio
- N/A
- 52-Week High
- $4.63
- 52-Week Low
- $2.30
- Avg Volume
- 85.26K
- Beta
- 1.51
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- Israel
- Employees
- 57